Cargando…
PRMT5 triggers glucocorticoid-induced cell migration in triple-negative breast cancer
Triple-negative breast cancers (TNBCs) are the most aggressive breast cancers, and therapeutic options mainly rely on chemotherapy and immunotherapy. Although synthetic glucocorticoids (GCs) are given to alleviate the side effects of these treatments, GCs and their receptor, the glucocorticoid recep...
Autores principales: | Noureddine, Lara Malik, Ablain, Julien, Surmieliova-Garnès, Ausra, Jacquemetton, Julien, Pham, Thuy Ha, Marangoni, Elisabetta, Schnitzler, Anne, Bieche, Ivan, Badran, Bassam, Trédan, Olivier, Hussein, Nader, Le Romancer, Muriel, Poulard, Coralie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Life Science Alliance LLC
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400884/ https://www.ncbi.nlm.nih.gov/pubmed/37536978 http://dx.doi.org/10.26508/lsa.202302009 |
Ejemplares similares
-
Glucocorticoid Receptor: A Multifaceted Actor in Breast Cancer
por: Noureddine, Lara Malik, et al.
Publicado: (2021) -
Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα
(+) breast cancer
por: Poulard, Coralie, et al.
Publicado: (2023) -
ERα-36 regulates progesterone receptor activity in breast cancer
por: Konan, Henri-Philippe, et al.
Publicado: (2020) -
The arginine methyltransferase PRMT1 regulates IGF-1 signaling in breast cancer
por: Choucair, Ali, et al.
Publicado: (2019) -
PRMT1, a Key Modulator of Unliganded Progesterone Receptor Signaling in Breast Cancer
por: Malbeteau, Lucie, et al.
Publicado: (2022)